Immunotherapy combo shows promise against tough throat cancer
NCT ID NCT03267498
First seen Jan 12, 2026 · Last updated May 24, 2026 · Updated 18 times
Summary
This study tested whether adding the immunotherapy drug nivolumab to standard chemoradiation helps patients with stage II to IVB nasopharyngeal cancer. Forty adults with this type of throat cancer took part. The main goal was to see if patients could complete all planned treatments, and researchers also looked at how well the cancer responded.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
National University Hospital Singapore
Singapore, 119074, Singapore
-
University of California, San Francisco
San Francisco, California, 94143, United States
Conditions
Explore the condition pages connected to this study.